Investigating levothyroxine drug release on synthesized nanocomposite containing magnetic cores covered with alginate polymer and metal-organic framework
Subject Areas : phytochemistryZaynab Madadi 1 , Fadaeian Manochehr 2 , Mohammad Ali Ghasemzade 3
1 - MSc, Department of Chemistry, Faculty of Basic Sciences, Qom Branch, Islamic Azad University, Qom, Iran
2 - Assistant Professor, Qom Branch, Islamic Azad University, Qom, Iran
3 - Associate Professor, Qom Branch, Islamic Azad University, Qom, Iran
Keywords: Metal-organic framework, Drug delivery-loading-release-levothyroxine, nanocomposite, Magnetic cores, Alginate polymer,
Abstract :
Objectives: Levothyroxine drug is used to treat thyroid diseases, which is one of the most common chronic diseases in the world, and considering that levothyroxine is a hydrophobic drug with low solubility and low stability, it requires an advanced drug delivery system. Among the targeted drug delivery systems, magnetically modified porous carriers have a high capacity to store drugs due to the presence of side groups, the adaptability of its porosity, and release it over a long period of time and instead of spreading throughout the body, it affects only the desired cell. he does.Materials and methods: The present research deals with preparing and identifying the metal-organic framework and investigating its performance in levothyroxine drug loading and release. First, MnCuFe2O4 nanoparticles were synthesized and covered by alginate polysaccharide. After that, the metal-organic framework 66-UiO was placed on it and the three-layer composite MnCuFe2O4@Alginate@UiO-66 was made.Findings: loading and release of levothyroxine drug on the synthesized nanocarrier was investigated at pH 7.4. The fabricated nanocomposite was examined by various methods such as SEM, EDX, FT-IR, BET. Nanocomposite was made with cheap and biodegradable raw materials such as alginate using an easy method with targeted drug delivery and magnetic strength.Conclusions: This nanocomposite with 87% loading capacity and 73% levothyroxine release can be used as a new and targeted drug delivery system.
l-thyroxine sodium salt hydrate both pure and in pharmaceutical formulations. Pharm. Biomed. Anal. 2016; 125: 33-40.
_||_